Zivo Bioscience, Inc.
ZIVO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001101026
No open-market purchases or sales by Zivo Bioscience, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17.6K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Zivo Bioscience, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 8 | 12 | +4 |
| Shares | 41.1K | 181.5K | +140.3K (+341.1%) |
| Value | $194.7K | $828.6K | +$633.8K (+325.5%) |
New holders (7)
Institutions that held Zivo Bioscience, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Credit Suisse AG | 45,132 | $206.0K | 0.00% |
| Jane Street Group, LLC | 41,934 | $191.0K | 0.00% |
| Two Sigma Investments, LP | 31,367 | $143.0K | 0.00% |
| Two Sigma Securities, LLC | 30,260 | $138.0K | 0.03% |
| Tower Research Capital LLC (TRC) | 11,177 | $51.0K | 0.00% |
| Verdence Capital Advisors LLC | 10,000 | $46.0K | 0.01% |
| UBS Group AG | 2,113 | $10.0K | 0.00% |
Sold out (3)
Institutions that held Zivo Bioscience, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Commonwealth Equity Services, LLC | 31,636 | $149.0K |
| Advisor Group Holdings, Inc. | 4 | $0 |
| Strategic Blueprint, LLC | 62 | $0 |